These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 34961908)

  • 1. Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates.
    Aoyama M; Tada M; Yokoo H; Demizu Y; Ishii-Watabe A
    Pharm Res; 2022 Jan; 39(1):89-103. PubMed ID: 34961908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fcγ Receptor Activation by Human Monoclonal Antibody Aggregates.
    Tada M; Aoyama M; Ishii-Watabe A
    J Pharm Sci; 2020 Jan; 109(1):576-583. PubMed ID: 31676270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity.
    Elter A; Yanakieva D; Fiebig D; Hallstein K; Becker S; Betz U; Kolmar H
    Front Immunol; 2021; 12():715719. PubMed ID: 34413859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Drug Conjugation and Loading on Target Antigen Binding and Cytotoxicity in Cysteine Antibody-Drug Conjugates.
    Nadkarni DV; Lee J; Jiang Q; Patel V; Sriskanda V; Dutta K; Meyer DM
    Mol Pharm; 2021 Mar; 18(3):889-897. PubMed ID: 33470823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cytotoxic conjugate of highly internalizing tetravalent antibody for targeting FGFR1-overproducing cancer cells.
    Poźniak M; Porębska N; Krzyścik MA; Sokołowska-Wędzina A; Jastrzębski K; Sochacka M; Szymczyk J; Zakrzewska M; Otlewski J; Opaliński Ł
    Mol Med; 2021 May; 27(1):46. PubMed ID: 33962559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Characterization of Therapeutic Monoclonal Antibodies by Using FcγR-expressing Reporter Cell Lines].
    Tada M; Ishii-Watabe A
    Yakugaku Zasshi; 2017; 137(7):837-843. PubMed ID: 28674297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agitation-Induced Aggregation of Lysine- And Interchain Cysteine-Linked Antibody-Drug Conjugates.
    Johann F; Wöll S; Winzer M; Gieseler H
    J Pharm Sci; 2024 May; 113(5):1265-1274. PubMed ID: 38070776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET-Guided Evaluation and Optimization of Internalized Antibody-Drug Conjugates Targeting Erythropoietin-Producing Hepatoma A2 Receptor.
    Jacobson O; Li Q; Chen H; Niu G; Kiesewetter DO; Xu L; Cook K; Yang G; Dall'Acqua W; Tsui P; Peng L; Chen X
    J Nucl Med; 2017 Nov; 58(11):1838-1844. PubMed ID: 28546337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors influencing the choice of monoclonal antibodies for antibody-drug conjugates.
    Hasan MM; Laws M; Jin P; Rahman KM
    Drug Discov Today; 2022 Jan; 27(1):354-361. PubMed ID: 34597756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110.
    Domínguez JM; Pérez-Chacón G; Guillén MJ; Muñoz-Alonso MJ; Somovilla-Crespo B; Cibrián D; Acosta-Iborra B; Adrados M; Muñoz-Calleja C; Cuevas C; Sánchez-Madrid F; Avilés P; Zapata JM
    J Hematol Oncol; 2020 Apr; 13(1):32. PubMed ID: 32264921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances with antibody-drug conjugates in breast cancer treatment.
    Abdus Subhan M; Torchilin VP
    Eur J Pharm Biopharm; 2021 Dec; 169():241-255. PubMed ID: 34748933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and Validation of a Cell-Based Binding Neutralizing Antibody Assay for an Antibody-Drug Conjugate.
    Xu W; Bano N; Guzman-Valdes O; Amberman J; Bandlamudi E; Khanna P; Carmean R; Helmy R
    AAPS J; 2024 Mar; 26(3):37. PubMed ID: 38548953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics.
    Thompson P; Fleming R; Bezabeh B; Huang F; Mao S; Chen C; Harper J; Zhong H; Gao X; Yu XQ; Hinrichs MJ; Reed M; Kamal A; Strout P; Cho S; Woods R; Hollingsworth RE; Dixit R; Wu H; Gao C; Dimasi N
    J Control Release; 2016 Aug; 236():100-16. PubMed ID: 27327768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody-Drug Conjugates.
    Li F; Ulrich M; Jonas M; Stone IJ; Linares G; Zhang X; Westendorf L; Benjamin DR; Law CL
    Mol Cancer Ther; 2017 Jul; 16(7):1347-1354. PubMed ID: 28341790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
    Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
    J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs.
    Andreev J; Thambi N; Perez Bay AE; Delfino F; Martin J; Kelly MP; Kirshner JR; Rafique A; Kunz A; Nittoli T; MacDonald D; Daly C; Olson W; Thurston G
    Mol Cancer Ther; 2017 Apr; 16(4):681-693. PubMed ID: 28108597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion.
    Dimasi N; Fleming R; Zhong H; Bezabeh B; Kinneer K; Christie RJ; Fazenbaker C; Wu H; Gao C
    Mol Pharm; 2017 May; 14(5):1501-1516. PubMed ID: 28245132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
    Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D
    PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
    Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
    Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Megakaryocyte Differentiation by Antibody-Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia.
    Zhao H; Gulesserian S; Ganesan SK; Ou J; Morrison K; Zeng Z; Robles V; Snyder J; Do L; Aviña H; Karki S; Stover DR; Doñate F
    Mol Cancer Ther; 2017 Sep; 16(9):1877-1886. PubMed ID: 28655784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.